PHARMACOLOG (Germany) Performance
| P750 Stock | 0.49 0.05 11.36% |
On a scale of 0 to 100, PHARMACOLOG holds a performance score of 8. The company owns a Beta (Systematic Risk) of -0.55, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning PHARMACOLOG are expected to decrease at a much lower rate. During the bear market, PHARMACOLOG is likely to outperform the market. Please check PHARMACOLOG's downside deviation, information ratio, and the relationship between the semi deviation and coefficient of variation , to make a quick decision on whether PHARMACOLOG's current price history will revert.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in PHARMACOLOG I UPPSALA are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, PHARMACOLOG reported solid returns over the last few months and may actually be approaching a breakup point. ...more
PHARMACOLOG |
PHARMACOLOG Relative Risk vs. Return Landscape
If you would invest 35.00 in PHARMACOLOG I UPPSALA on October 25, 2024 and sell it today you would earn a total of 14.00 from holding PHARMACOLOG I UPPSALA or generate 40.0% return on investment over 90 days. PHARMACOLOG I UPPSALA is generating 0.9255% of daily returns assuming 8.6958% volatility of returns over the 90 days investment horizon. Simply put, 77% of all stocks have less volatile historical return distribution than PHARMACOLOG, and 82% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
PHARMACOLOG Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for PHARMACOLOG's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as PHARMACOLOG I UPPSALA, and traders can use it to determine the average amount a PHARMACOLOG's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1064
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | P750 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 8.7 actual daily | 77 77% of assets are less volatile |
Expected Return
| 0.93 actual daily | 18 82% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average PHARMACOLOG is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PHARMACOLOG by adding it to a well-diversified portfolio.
Things to note about PHARMACOLOG I UPPSALA performance evaluation
Checking the ongoing alerts about PHARMACOLOG for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for PHARMACOLOG I UPPSALA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| PHARMACOLOG is way too risky over 90 days horizon | |
| PHARMACOLOG has some characteristics of a very speculative penny stock | |
| PHARMACOLOG appears to be risky and price may revert if volatility continues |
- Analyzing PHARMACOLOG's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PHARMACOLOG's stock is overvalued or undervalued compared to its peers.
- Examining PHARMACOLOG's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating PHARMACOLOG's management team can have a significant impact on its success or failure. Reviewing the track record and experience of PHARMACOLOG's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of PHARMACOLOG's stock. These opinions can provide insight into PHARMACOLOG's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for PHARMACOLOG Stock analysis
When running PHARMACOLOG's price analysis, check to measure PHARMACOLOG's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PHARMACOLOG is operating at the current time. Most of PHARMACOLOG's value examination focuses on studying past and present price action to predict the probability of PHARMACOLOG's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PHARMACOLOG's price. Additionally, you may evaluate how the addition of PHARMACOLOG to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |